A Study of ASP2215 in Combination With Induction and Consolidation Chemotherapy in Patients With Newly Diagnosed Acute Myeloid Leukemia.

  • STATUS
    Recruiting
  • End date
    Mar 31, 2022
  • participants needed
    93
  • sponsor
    Astellas Pharma Inc
Updated on 17 June 2021
Investigator
Medical Affairs Europe
Primary Contact
Site JP81019 (6.3 mi away) Contact
+58 other location
cytarabine
potassium
gilbert's syndrome
induction chemotherapy
consolidation therapy
serum bilirubin level
idarubicin
neoadjuvant therapy
flt3 internal tandem duplication
consolidation chemotherapies

Summary

The purpose of phase 1 part in this study is to determine the maximum tolerated dose (MTD) and/or recommended expansion dose (RED) of ASP2215 concomitant with cytarabine/idarubicin as induction chemotherapy based on the status of the onset of dose-limiting toxicity (DLT) in newly diagnosed Acute Myeloid Leukemia (AML) subjects. Phase 1 part will also evaluate safety and tolerability and characterize the pharmacokinetic (PK) parameters of ASP2215 concomitant with induction and consolidation chemotherapy as well as evaluate the PK parameters of cytarabine concomitant with ASP2215.

The purpose of phase 2 part is to evaluate efficacy of ASP2215 in combination with induction therapy. Phase 2 cohort will also evaluate safety and characterize the PK parameters of ASP2215 in combination with induction and consolidation therapy followed by maintenance therapy in newly diagnosed FLT3-mutated AML subjects.

Description

This study is composed of Phase 1 part (the dose-evaluation part and the expansion part) and Phase 2 part.

In the dose-evaluation part of Phase 1 part, at least 3 subjects will receive ASP2215 at each dose (low, middle, and high) for determination of MTD and/or RED. Treatment of AML in Phase 1 part is composed of 3 periods of therapy: remission induction, consolidation, and maintenance. The decision of whether or not to proceed to the next dose will be made based on the occurrence of DLT during Cycle 1 of the induction period.

In the expansion part of Phase 1 part, a maximum of 3 subjects will receive ASP2215 at RED that has been recommended in the dose-evaluation part and the safety will be assessed based on the onset of DLTs during Cycle 1 of the induction and consolidation periods.

In Phase 2 part, Subjects will receive ASP2215 at the recommended dose established in Phase 1 part. The target population will be limited to newly diagnosed FLT3-mutated AML.

New locations for Phase 2 part will be selected and added, while locations for Phase 1 part are shown as 'Completed'.

Details
Condition Acute myeloid leukemia, Acute Myelogenous Leukemia (AML), FLT3-mutated Acute Myeloid Leukemia, FLT3-mutated Acute Myeloid Leukemia, FLT3-mutated Acute Myeloid Leukemia, FLT3-mutated Acute Myeloid Leukemia, FLT3-mutated Acute Myeloid Leukemia, FLT3-mutated Acute Myeloid Leukemia, FLT3-mutated Acute Myeloid Leukemia, FLT3-mutated Acute Myeloid Leukemia, FLT3-mutated Acute Myeloid Leukemia, FLT3-mutated Acute Myeloid Leukemia, FLT3-mutated Acute Myeloid Leukemia, FLT3-mutated Acute Myeloid Leukemia, FLT3-mutated Acute Myeloid Leukemia, FLT3-mutated Acute Myeloid Leukemia, acute myelogenous leukemia, anll, acute myeloblastic leukemia, FLT3-mutated Acute Myeloid Leukemia, FLT3-mutated Acute Myeloid Leukemia, FLT3-mutated Acute Myeloid Leukemia, FLT3-mutated Acute Myeloid Leukemia, FLT3-mutated Acute Myeloid Leukemia, FLT3-mutated Acute Myeloid Leukemia, FLT3-mutated Acute Myeloid Leukemia, FLT3-mutated Acute Myeloid Leukemia, FLT3-mutated Acute Myeloid Leukemia, FLT3-mutated Acute Myeloid Leukemia, FLT3-mutated Acute Myeloid Leukemia, FLT3-mutated Acute Myeloid Leukemia, FLT3-mutated Acute Myeloid Leukemia
Treatment cytarabine, Idarubicin, Gilteritinib
Clinical Study IdentifierNCT02310321
SponsorAstellas Pharma Inc
Last Modified on17 June 2021

Eligibility

Yes No Not Sure

Inclusion Criteria

[Phase 1 part]
Subject is defined as having previously untreated de novo AML according to the World Health Organization (WHO) criteria (2008) within 28 days prior to study enrollment
Subject has an Eastern Cooperative Oncology Group (ECOG) performance status of 2
Subject must meet all of the following criteria in the laboratory test at screening
Serum aspartate aminotransferase (AST) and alanine aminotransferase (ALT) levels of 2.5 institutional upper limit of normal (ULN)
Total serum bilirubin level of 1.5 institutional ULN
Serum creatinine level of 1.5 institutional ULN or an estimated glomerular filtration rate (eGFR) of > 50 mL/min
Subject is suitable for oral administration of ASP2215
Female subject falls under the following
Of non-childbearing potential
Post-menopausal (defined as at least 1 year with no menses without a medical reason such as drug administration) at screening, or
Documented surgically sterile or status post-hysterectomy (at least 1 month prior to screening)
Of childbearing potential
Has a negative result for the pregnancy test at screening, and
Agrees to use an appropriate contraception starting at screening and throughout the study period and for 60 days after the final study drug administration
Female subject agrees not to breastfeed starting at screening and throughout the study period and for 60 days after the final study drug administration
Female subject agrees not to donate ova starting at screening and throughout the study period and for 60 days after the final study drug administration
Male subject and his female spouse/partner who is of childbearing potential agrees to use an appropriate contraception starting at screening and throughout the study period and for 120 days after the final study drug administration
Male subject agrees not to donate sperm starting at screening and throughout the study period and for 120 days after the final study drug administration
Subject agrees not to participate in another interventional study while on study treatment
Subject can be admitted during the induction period
[Phase 2 part]
Subject has a diagnosis of previously-untreated de novo acute myeloid leukemia (AML) according to World Health Organization (WHO) classification (2017) documented within 28 days prior to enrollment
Subject is positive for FLT3-ITD and/or TKD mutation in bone marrow or whole blood as determined by the central lab. Registration by the local lab result is not acceptable
Subject has an ECOG performance status (PS) 0 to 1. Subject who has an ECOG PS 2 is eligible only if the primary disease related symptoms such as pneumonia and febrile neutropenia are the cause of PS score
Subject is suitable for oral administration of ASP2215
Female subject is not pregnant and at least 1 of the following conditions apply
Not a woman of childbearing potential (WOCBP)
WOCBP who agrees to follow the contraceptive guidance from the time of informed consent through at least 180 days after final study treatment administration
Female subject must agree not to breastfeed starting at screening and throughout the study period, and for 60 days after the final study drug administration
Female subject must not donate ova starting at screening and throughout the study period, and for 180 days after the final study drug administration
Male subject and their female partners who are of childbearing potential must be using highly effective contraception per locally accepted standards in addition to a barrier method starting at screening and continue throughout the study period and for 120 days after the final study drug administration
Male subject must not donate sperm starting at screening and throughout the study period and for 120 days after the final study drug administration
Male subject with pregnant partner(s) must agree to remain abstinent or use a condom for the duration of the pregnancy throughout the study period and for 120 days after the final study treatment administration
Subject agrees not to participate in another interventional study while on treatment
Subject must meet the following criteria as indicated on the clinical laboratory
tests
Serum creatinine 1.5 institutional upper limit of normal (ULN), or if serum creatinine outside normal range, then glomerular filtration rate (GFR) > 50 mL/min/1.73m^2 as calculated with the 4-parameter Modification of Diet in Renal Disease (MDRD) equation
Serum total bilirubin 2.5 mg/dL (43 mol/L), except for subjects with Gilbert's syndrome
Serum aspartate aminotransferase (AST) and alanine aminotransferase (ALT) < 3 x ULN. If liver abnormality by the primary disease is suspected, subject may be pre-registered to initiate the chemotherapy. Prior to registration, AST/ALT values must meet the criteria to continue the study
Serum magnesium institutional lower limit of normal (LLN). Subject may pre-register without magnesium value, but subject must meet the criteria prior to the full registration on Day 8
Serum potassium institutional lower limit of normal (LLN)

Exclusion Criteria

[Phase 1 part]
Subject was diagnosed with acute promyelocytic leukemia (APL)
Subject has breakpoint cluster region-abelson (BCR-ABL)-positive leukemia (chronic myelogenous leukemia in blast crisis)
Subject has active malignant tumors other than AML or myelodysplastic syndrome (MDS)
Subject has received prior AML treatment except for the following
Urgent leukapheresis
Hydroxyurea administration for emergency treatment of hyperleukocytosis ( 7 days)
Administration of retinoic acid before the diagnosis to exclude APL ( 7 days)
Supportive care using growth factors or cytokines
Steroid administration to treat hypersensitivity or blood transfusion reactions
Subject has clinically active central nervous system leukemia
Subject has disseminated intravascular coagulation (DIC)
Subject has had major surgery within 28 days prior to the first study drug administration
Subject has had radiation therapy within 28 days prior to the first study drug administration
Subject has congestive heart failure of New York Heart Association (NYHA) class 3 or 4, or subject with a past history of congestive heart failure of NYHA class 3 or 4 and in whom echocardiogram (ECHO) or Multiple Gate Acquisition (MUGA) scan performed within 3 months prior to screening or at screening showed a left ventricular ejection fraction (LVEF) of < 45%
Subject has cardiac impairment or a clinically significant cardiac disease, including any one of the following
Complete left bundle branch block
Obligate use of a cardiac pacemaker
Long QT syndrome at Screening
Prolongation of the QTc interval (> 450 ms) on electrocardiogram (ECG) at screening
Right bundle branch block + left anterior hemiblock (bifascicular block)
Angina pectoris within 3 months prior to study drug administration
Acute myocardial infarction within 3 months prior to study drug administration
Subject requires treatment with concomitant drugs that are strong inducers of cytochrome P450 (CYP)3A
Subject requires treatment with concomitant drugs that are strong inhibitors or inducers of P glycoprotein (P-gp) with the exception of drugs that are considered absolutely essential for the care of the subject
Subject requires treatment with concomitant drugs that target serotonin 5HT1 or 5HT2B receptors or sigma receptors, with the exception of drugs that are considered absolutely essential for treatment of the subject
Subject has an active uncontrollable infection
Subject is known to have human immunodeficiency virus (HIV) infection
Subject has active hepatitis B or C or other active hepatic disorders
Subject has any condition that, in the investigator's or sub-investigator's opinion, makes the subject unsuitable for study participation
Potassium and magnesium levels of below institutional lower limit of normal in the laboratory test at screening
[Phase 2 part]
Subject was diagnosed with acute promyelocytic leukemia (APL)
Subject has known BCR-ABL-positive leukemia (chronic myelogenous leukemia in blast crisis)
Subject has therapy-related AML
Subject has active malignant tumors other than AML
Subject has received previous therapy for AML, with the exception of the following
Emergency leukapheresis
Emergency treatment for hyperleukocytosis with hydroxyurea for 10 days
Preemptive treatment with retinoic acid prior to exclusion of APL 7 days
Growth factor or cytokine support
Steroids for the treatment of hypersensitivity or transfusion reactions
Subject has QTcF interval > 450 ms (average of triplicate determinations based on central reading)
Subject with long QT syndrome
Subject has clinically active central nervous system leukemia
Subject has had major surgery within 4 weeks prior to the first study dose
Subject has radiation therapy within 4 weeks prior to the first study dose
Subject has immediate life-threatening, severe complications of leukemia such as severe uncontrolled bleeding and/or severe disseminated intravascular coagulation
Subject is known to have human immunodeficiency virus infection
Subject has active hepatitis B or C
Subject has an uncontrolled infection. An infection controlled with an approved or closely monitored antibiotic/antiviral/antifungal treatment is allowed
Subject has uncontrolled angina, severe uncontrolled ventricular arrhythmias, electrocardiographic evidence of acute ischemia, congestive heart failure New York Heart Association (NYHA) class 3 or 4 or subject has a history of congestive heart failure of NYHA class 3 or 4 and echocardiogram (ECHO) or Multiple Gate Acquisition (MUGA) scan performed within 3 months prior to screening or at screening showed a left ventricular ejection fraction (LVEF) of < 45%
Subject requires treatment with concomitant drugs that are strong inducers of cytochrome P450 (CYP) 3A
Subject requires treatment with concomitant drugs that target serotonin 5HT2B receptors or sigma nonspecific receptors, with the exception of drugs that are considered absolutely essential for treatment of the subject
Subject requires treatment with concomitant drugs that are strong inhibitors or inducers of P glycoprotein (P-gp) with the exception of drugs that are considered absolutely essential for the care of the subject
Subject has prior malignancies, except resected basal cell carcinoma or treated cervical carcinoma in situ. Cancer treated with curative intent 5 years previously will be allowed. Cancer treated with curative intent < 5 years previously will not be allowed
Subject has any condition which makes the subject unsuitable for study participation
Clear my responses

How to participate?

Step 1 Connect with a site
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar
Name

Primary Contact

site
Name

Phone Email

0/250
Preferred Language
Other Language
Please verify that you are not a bot.

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider

Loading...

Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 

 • 

Private

Reply by • Private
Loading...

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.
Loading...

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note